Skip to main content

Table 3 Modified Intention to Treat efficacy and effectiveness of studies examining oral PrEP

From: A systematic review of adherence to oral pre-exposure prophylaxis for HIV – how can we improve uptake and adherence?

Characteristics

Outcome

Year

Study name

Population

Regimen

Drug

Efficacy (%, 95 CI)

2010

iPrEx [6]

MSM/TGW

Daily

TDF-FTC

44% (15 to 63)

2012

Partners study [7]

Heterosexual HIV-discordant couples

Daily

TDF-FTC

75% (55 to 87)

TDF

67% (44 to 81)

2012

TDF2 [8]

Heterosexual

Daily

FTC- TDF

62.2% (21.5 to 83.4)

2012

FEM-PrEP [13]

Heterosexual Females

Daily

TDF-FTC

6% (−52 to 41%)

2013

Bangkok tenofovir study [31]

PWID

Daily

TDF

48.9% (9.6 to 72.2)

2014

iPrEx extension [15]

MSM/TGW

Daily

TDF-FTC

36% (−24 to 67)a

2015

VOICE [14]

Heterosexual Females

Daily

TDF-FTC

−4% (−49 to 27)

TDF

−49% (− 129 to 3)

2015

PROUD [9]

MSM

Daily

TDF-FTC

86% (90% CI 64 to 96)

2015

IPERGAY [10]

MSM/TGW

Event-driven

TDF-FTC

86% (40 to 98)

  1. a Unknown if intention to treat or modified intention to treat. MSM men who have sex with men, TGW transgender women, PWID people who inject drugs, TDF tenofovir, FTC emtricitabine